TL;DR
This paper uses cryo-EM to reveal the first high-resolution structure of the leptin receptor (LepR) signaling complex, uncovering an asymmetric mechanism of activation where a single leptin molecule dimerizes two LepR units. This structural insight explains obesity-associated mutations and enables the design of biased leptin agonists that selectively modulate downstream signaling pathways, offering new therapeutic avenues for obesity.
What Problem Does This Paper Address?
Obesity is a major health crisis, and leptin, a hormone that regulates appetite and energy balance, plays a crucial role. While leptin is known to activate the leptin receptor (LepR) to signal satiety, this pathway is often dysregulated in obese individuals, leading to leptin resistance. Despite extensive research, the precise molecular mechanism by which leptin activates LepR has remained elusive, hindering the development of effective leptin-based therapies. Previous structural studies were limited by low resolution and the instability of the leptin-LepR complex. This paper aims to resolve this structural mystery to understand how leptin binding leads to receptor activation and to identify potential targets for therapeutic intervention.
Methods
The researchers employed single-particle cryo-electron microscopy (cryo-EM) to determine the structure of the leptin-LepR signaling complex. To overcome the inherent instability of the complex, they engineered a stabilized version of the LepR extracellular domain by fusing it with dimerizing leucine zippers. They then determined structures at resolutions of 5.9 Å and 4.5 Å for different constructs, and a focused refinement yielded a 3.8 Å resolution map of the leptin-LepR binding interface. Molecular models were built by docking AlphaFold predictions into these maps. To investigate the functional consequences of their structural findings, they used site-directed mutagenesis to create leptin and LepR variants and assessed their signaling activity in HEK-293T cells using Western blotting (for STAT3, SHP2, ERK phosphorylation) and flow cytometry. They also designed and tested biased leptin agonists.
Datasets
Not discussed in the paper.
Key Insights and Ideas
- Asymmetric Dimerization: The leptin-LepR complex adopts an asymmetric architecture, where one leptin molecule binds to two LepR subunits, but not in a symmetrical fashion. This is a departure from the typical symmetric interactions seen in many cytokine receptor complexes.
- Dual Binding Sites: Leptin engages LepR through two distinct binding sites: a high-affinity "site 2" on the CHR2 domain and a lower-affinity "site 3" on the Ig domain. Notably, the canonical "site 1" interaction, common in other cytokine receptors, is unoccupied.
- Structural Basis for Obesity Mutations: The high-resolution structures reveal how specific mutations associated with human obesity disrupt the leptin-LepR interaction at both site 2 and site 3, providing a molecular explanation for leptin resistance.
- Leptin Conformational Change: LepR binding induces significant conformational changes in leptin, particularly in its AB and CD loops, which are crucial for stabilizing the site 3 interaction and facilitating receptor dimerization.
- Design of Biased Agonists: Understanding the structural basis of LepR activation allowed for the rational design of leptin variants that act as "biased agonists." These variants can selectively activate the STAT3 pathway (associated with satiety) while downregulating pathways linked to leptin resistance (SHP2/ERK), offering a potential strategy to overcome leptin resistance in obesity.
Key Results
- The cryo-EM structure of the leptin-LepR complex was determined at resolutions of 5.9 Å, 4.5 Å, and 3.8 Å for the binding interface.
- The structure revealed an asymmetric 2:2 leptin-LepR complex, with one leptin binding to two LepR chains, and the second leptin binding to only one LepR chain.
- Mutagenesis studies confirmed the importance of specific leptin and LepR residues at site 2 and site 3 for LepR activation and STAT3 signaling.
- Leptin variants designed to destabilize the asymmetric LepR dimer showed partial agonism, with some exhibiting biased signaling towards STAT3 over SHP2/ERK.
- High-affinity biased leptin agonists were developed that could suppress STAT3 activation and SOCS3 expression even in the presence of wild-type leptin, acting as "receptor signaling clamps."
Limitations and Future Work
The authors acknowledge that while their structure represents a stable conformation, transient or dynamic equilibria with other complex forms (e.g., a fully closed 2:2 complex or a 3:3 complex) cannot be entirely ruled out. They also note that direct assessment of site-specific LepR ICD phosphorylation with available reagents was not possible, and further biochemical analysis is needed to fully distinguish between different mechanisms for biased signaling. Future work could focus on further characterizing the functional role of the symmetric 3:3 assembly and developing more refined biased LepR agonists for therapeutic applications.
Summary updated